Vicinitas Therapeutics: The company raised $65 million of Series A venture funding in a deal led by Deerfield Management and Andreessen Horowitz on July 28, 2022. GV, The Mark Foundation for Cancer Research, Berkeley Catalyst Fund, and Droia Oncology Ventures also participated in the round. The company is a developer of differentiated disease therapy designed to restore the levels of aberrantly degraded proteins.
Elation Health: The company raised $50 million of Series D venture funding in a deal led by Ascension Ventures and Generation Investment Management on July 25, 2022, putting the company’s pre-money valuation at $350 million. Ascend Partners (Healthcare), Threshold Ventures, Jonathan Bush, Fay Rotenberg and other undisclosed investors also participated in the round. The company is a developer of a secured healthcare application designed to strengthen the physician-patient relationship.
AltPep: The company raised $44.4 million of venture funding from undisclosed investors on July 26, 2022. The company is an operator of a proprietary peptide-based platform intended to diagnose and neutralize toxic precursors to amyloid diseases.
Novasenta: The company raised $40 million of Series A venture funding in a deal led by UPMC Enterprises on July 29, 2022. The company is a developer of a pharmaceutical drug intended to provide immunotherapy treatment for cancer.
BridGene Biosciences: The company raised $38.5 million of Series B venture funding from Lapam Capital, DYEE Capital and Junson Capital on July 27, 2022. The company is a developer of innovative and small molecules intended to treat traditionally undruggable targets.
Syapse: The company raised $35 million of venture funding in a deal led by Innovatus Capital Partners on July 28, 2022. Merck & Co., Ally Bridge Group, Northpond Ventures, Revelation Partners, Social Capital, Safeguard Scientifics other undisclosed investors also participated in the round. The company is a developer of insights and a data-sharing network designed to deliver precision cancer care.
Ozette: The company raised $26 million of Series A venture funding in a deal led by Madrona Venture Group on July 28, 2022. M12, Alexandria Venture Investments, OCV Partners, Duke University, and Cercano Management also participated in the round. The company is a developer of single-cell immune monitoring platform intended for cell discovery and annotation of the human immune system.
Peachy: The company raised $25.1 million of venture funding from undisclosed investors on July 28, 2022. The company is an operator of Botox studios designed to offer wrinkle treatments, prescription retinoids, and sunscreen products.
Arine: The company raised $18.5 million of Series B venture funding from Katalyst Ventures and other undisclosed investors on July 26, 2022, putting the company’s pre-money valuation at $110 million. The company is an operator of medication management platform designed to improve the health and quality of life.
SEngine Precision Medicine: The company raised $10 million of Series A2 venture funding in a deal led by WRF Capital on July 28, 2022. Alethea Capital Management, Vincere Capital Biotech, Bangarang Group and other undisclosed investors also participated in the round. The company is an operator of an oncology diagnostic firm intended to identify and develop the next generation of cancer-targeted drugs.
MatriSys Bioscience: The company raised $8.4 million of venture funding from Mesa Verde Venture Partners, ACE Fund and other undisclosed investors on July 27, 2022. The company is a developer of rational microbiome therapies designed to treat patients suffering from skin diseases.
NEOsphere Biotechnologies: The company raised an undisclosed amount of Series A venture funding from Ventura BioMed Investors and other undisclosed investors on July 25, 2022. The company is a developer of proteomics intended to create value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets.
